PCSK9 and diabetes mellitus: Additionally, therapies such as incretins and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, which support treatments for related conditions, such as diabetes and hypertension, have shown potential in reducing the overall cardiometabolic risk [21].